Document text
Principal Investigator: Barney Graham
Organization: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Fiscal Year: 2021
Award: $522,460
Funding agency: National Institute of Allergy and Infectious Diseases
When the MERS CoV outbreak raised global health concerns, we initiated a program to develop a candidate vaccine. Based on prior studies to solve the spike structure of HKU1 (an endemic betacoronavirus) and finding stabilizing mutations that also stabilized MERS-CoV and SARS-CoV spike proteins, and prior research collaboration agreements with industry, we were able to respond quickly to the emergence SARS-CoV-2. When sequences were available we immediately ordered reagents to produce spike protein for structural studies, for the development of serological assays, and for probes to isolate B cells from survivors for antibody discovery. In collaboration with Moderna, we used information from our prior studies to develop a mRNA vaccine based on the stabilized spike structure of SARS-CoV-2. To characterize this vaccine we conducted in vivo studies in hamsters, mice and NHPs. Our recent work has focused on assessing the immune response following vaccination, understanding the impact of viral variants on immunization and attempting to define a correlate of protection. Immunization of hamsters, mice and NHPs with mRNA-1273 proved to be immunogenic and elicit a neutralizing humoral response. We showed it protects both upper and lower airway infection in mice and NHPs. We have also learned that mRNA-1273 elicited S-specific antibody levels correlated with the amount of viral replication in the upper and lower airway following SARS-CoV-2 challenge in NHPs. Furthermore, our studies have shown that the number of immunizations impacts protection and that a two-dose mRNA-1273 vaccine regimen protects NHPs from beta infection. This work has validated the prototype pathogen approach to pandemic preparedness that we have advocated as a proactive method that would systematically establish the reagents and knowledge base needed to address all 25 virus families known to infect humans. The steps taken to make this unprecedented response to a new viral pandemic threat will serve as a template for responses to future emerging viruses.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><Address><Advocate><Agreement><Antibodies><B blood cells><B cell><B cells><B-Cells><B-Lymphocytes><B-cell><COVID-19 outbreak><COVID-19 virus><COVID19 outbreak><COVID19 virus><CoV S protein><CoV glycoprotein S><CoV spike glycoprotein><CoV spike protein><CoV-2><CoV2><Collaborations><Coronaviridae><Coronaviridae Infections><Coronavirus><Coronavirus Infections><Coronavirus glycoprotein S><Coronavirus spike protein><Cricetinae><Development><Disease Outbreaks><Dose><Family><Future><Genetic Alteration><Genetic Change><Genetic defect><Goals><Hamsters><Hamsters Mammals><Hu-mABs><Human><Immune response><Immunization><Immunologic Sensitization><Immunologic Stimulation><Immunological Sensitization><Immunological Stimulation><Immunological response><Immunostimulation><Industry><Infection><MERS corona virus><MERS coronavirus><MERS virus><MERS-CoV><Methods><Mice><Mice Mammals><Middle East Respiratory Syndrome Corona Virus><Middle East Respiratory Syndrome Coronavirus><Middle East Respiratory Syndrome Virus><Middle East Respiratory Syndrome-CoV><Middle Eastern Respiratory Syndrome Corona virus><Middle Eastern Respiratory Syndrome Coronavirus><Middle Eastern Respiratory Syndrome Virus><Middle Eastern Respiratory Syndrome-CoV><Modern Man><Moderna COVID-19 vaccine><Moderna coronavirus disease 2019 vaccine><Murine><Mus><Mutation><Outbreaks><Prevention><Proteins><Public Health><RNA vaccine><RNA-based vaccine><Reagent><Regimen><Research><SARS Virus><SARS corona virus><SARS corona virus 2><SARS coronavirus><SARS-Associated Coronavirus><SARS-CoV><SARS-CoV-2><SARS-CoV-2 outbreak><SARS-CoV2><SARS-CoV2 outbreak><SARS-Related Coronavirus><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Serology test><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome Virus><Severe Acute Respiratory Syndrome corona virus><Severe Acute Respiratory Syndrome coronavirus><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 outbreak><Severe acute respiratory syndrome related corona virus 2><Structure><Survivors><Technology><Vaccination><Vaccines><Variant><Variation><Viral><Virus><Virus Replication><Work><Wuhan coronavirus><base><beta CoV><beta coronavirus><betaCoV><betacoronavirus><corona virus><coronavirus S protein><coronavirus disease 2019 outbreak><coronavirus disease 2019 virus><coronavirus spike glycoprotein><coronavirus vaccine><develop a vaccine><development of a vaccine><developmental><genome mutation><global health><hCoV19><host response><humAbs><human mAbs><human monoclonal antibodies><human monoclonals><immune system response><immunogenic><immunoresponse><in vivo><insight><knowledge base><knowledgebase><mRNA vaccine><mRNA-1273><mRNA-based vaccine><mRNA1273><nCoV2><pan CoV vaccine><pan coronavirus vaccine><pandemic><pandemic disease><pandemic preparedness><pathogen><programs><prototype><response><serology assay><severe acute respiratory syndrome-CoV><universal CoV vaccine><universal coronavirus vaccine><vaccine against coronavirus><vaccine candidate><vaccine development><vaccine formulation><viral multiplication><viral replication><virus multiplication><β CoV><β coronavirus><βCoV>